Abstract
Thirty-two patients with systemic lupus erythematosus were evaluated clinically and with computed tomography in order to determine whether the occurrence of cerebral atrophy in systemic lupus erythematosus was due to the steroid therapy or the cerebral manifestations of the disease itself. Of these patients, 14 had central nervous system manifestations of the disease (lupus cerebritis) and 12 of the 14 were on long-term steroid therapy. Eighteen patients had no clinical evidence of lupus cerebritis and all were on long-term steroids. Of the 14 lupus cerebritis patients, 10 showed moderate cerebral atrophy, four minimal atrophy, and none were normal. Of the 18 patients without lupus cerebritis, none had moderate atrophy, six (33%) showed minimal atrophy, and 12 (67%) had normal CT scans. This data suggest that it is the lupus cerebritis rather than the therapy that is responsible for the moderate cerebral atrophy. In patients suspected of lupus cerebritis, steroids should not be withheld because of concern for steroid-induced atrophy. Rather, the dose may need to be increased.
| Original language | English |
|---|---|
| Pages (from-to) | 21-23 |
| Number of pages | 3 |
| Journal | American Journal of Neuroradiology |
| Volume | 3 |
| Issue number | 1 |
| State | Published - Dec 1 1982 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
- Radiology Nuclear Medicine and imaging
- Radiological and Ultrasound Technology
Cite this
Cerebral atrophy in systemic lupus erythematosus : Steroid- or disease-induced phenomenon? / Ostrov, S. G.; Quencer, Robert; Gaylis, N. B.; Altman, Roy D.
In: American Journal of Neuroradiology, Vol. 3, No. 1, 01.12.1982, p. 21-23.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cerebral atrophy in systemic lupus erythematosus
T2 - Steroid- or disease-induced phenomenon?
AU - Ostrov, S. G.
AU - Quencer, Robert
AU - Gaylis, N. B.
AU - Altman, Roy D
PY - 1982/12/1
Y1 - 1982/12/1
N2 - Thirty-two patients with systemic lupus erythematosus were evaluated clinically and with computed tomography in order to determine whether the occurrence of cerebral atrophy in systemic lupus erythematosus was due to the steroid therapy or the cerebral manifestations of the disease itself. Of these patients, 14 had central nervous system manifestations of the disease (lupus cerebritis) and 12 of the 14 were on long-term steroid therapy. Eighteen patients had no clinical evidence of lupus cerebritis and all were on long-term steroids. Of the 14 lupus cerebritis patients, 10 showed moderate cerebral atrophy, four minimal atrophy, and none were normal. Of the 18 patients without lupus cerebritis, none had moderate atrophy, six (33%) showed minimal atrophy, and 12 (67%) had normal CT scans. This data suggest that it is the lupus cerebritis rather than the therapy that is responsible for the moderate cerebral atrophy. In patients suspected of lupus cerebritis, steroids should not be withheld because of concern for steroid-induced atrophy. Rather, the dose may need to be increased.
AB - Thirty-two patients with systemic lupus erythematosus were evaluated clinically and with computed tomography in order to determine whether the occurrence of cerebral atrophy in systemic lupus erythematosus was due to the steroid therapy or the cerebral manifestations of the disease itself. Of these patients, 14 had central nervous system manifestations of the disease (lupus cerebritis) and 12 of the 14 were on long-term steroid therapy. Eighteen patients had no clinical evidence of lupus cerebritis and all were on long-term steroids. Of the 14 lupus cerebritis patients, 10 showed moderate cerebral atrophy, four minimal atrophy, and none were normal. Of the 18 patients without lupus cerebritis, none had moderate atrophy, six (33%) showed minimal atrophy, and 12 (67%) had normal CT scans. This data suggest that it is the lupus cerebritis rather than the therapy that is responsible for the moderate cerebral atrophy. In patients suspected of lupus cerebritis, steroids should not be withheld because of concern for steroid-induced atrophy. Rather, the dose may need to be increased.
UR - http://www.scopus.com/inward/record.url?scp=0020471399&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020471399&partnerID=8YFLogxK
M3 - Article
C2 - 6800237
AN - SCOPUS:0020471399
VL - 3
SP - 21
EP - 23
JO - American Journal of Neuroradiology
JF - American Journal of Neuroradiology
SN - 0195-6108
IS - 1
ER -